Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration
Jean-sébastien Hulot
Journal of the American College of Cardiology, 2010
View PDFchevron_right
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel: A Meta-Analysis
Ross McKinnon
Circulation: Cardiovascular Genetics, 2014
View PDFchevron_right
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis
Betti Giusti
The Pharmacogenomics Journal, 2010
View PDFchevron_right
Cytochrome P450 2C19 Polymorphisms and Its Association With Major Adverse Cardiac Events in Post-coronary Intervention Patients on Clopidogrel in the Tertiary Care Center
Nikhil Kambhampati
Cureus, 2023
View PDFchevron_right
A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users
Stuart Head
Genetics in medicine : official journal of the American College of Medical Genetics, 2015
View PDFchevron_right
PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients
Jelena Cukic
Clinical and Experimental Pharmacology and Physiology, 2016
View PDFchevron_right
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?
rohit arora
Indian heart journal
View PDFchevron_right
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
gilbert bensimon
Lancet, 2009
View PDFchevron_right
Genetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease
Behzad Poopak
Research in Molecular Medicine
View PDFchevron_right
Meta-analyses of the association between cytochrome CYP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary …
Michel Zabalza
Heart, 2011
View PDFchevron_right
Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region
rania Abdelhedi
World Journal of Cardiovascular Diseases, 2013
View PDFchevron_right
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes
Jan Cornel
JAMA Cardiology, 2019
View PDFchevron_right
(Frequency of CYP2C19 Gene Polymorphisms (SNP) and its Impact on Clinical Outcome in Ischemic Heart Disease Patients Taking Clopidogrel after percutaneous coronary intervention (PCI
Khaled Baraka
Journal of medical and pharmaceutical sciences, 2019
View PDFchevron_right
CYP2C19pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials
Sahar Ahmed
Catheterization and Cardiovascular Interventions, 2018
View PDFchevron_right
CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina
Ho-Sook Kim
Circulation: Cardiovascular Genetics, 2013
View PDFchevron_right
PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel—A Systematic Review and Meta-Analysis
Judit Bajor
Frontiers in Physiology
View PDFchevron_right
CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
Koroush Khalighi
Journal of community hospital internal medicine perspectives, 2017
View PDFchevron_right
Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction
Richard Bach
Circulation: Cardiovascular Genetics, 2014
View PDFchevron_right
Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis
Most. Sumaiya Khatun Kali
Platelets, 2020
View PDFchevron_right
Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
Saoussen Chouchene
European Journal of Clinical Pharmacology, 2018
View PDFchevron_right
Research Highlights: CYP2C19 genetic variants and clopidogrel responsiveness in acute coronary syndrome: are we ready for individualized therapy?
Betti Giusti
Pharmacogenomics, 2009
View PDFchevron_right
The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis
Abdullah Alkattan
Egyptian Journal of Medical Human Genetics, 2022
View PDFchevron_right
Association of Polymorphisms in CYP2C19 with the Efficacy of Clopidogrel Therapy in South Indian Patients Undergoing Percutaneous Coronary Intervention
Vijay Kumar Kutala
Journal of cardiovascular disease research, 2017
View PDFchevron_right
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Pascale GAUSSEM
Blood, 2006
View PDFchevron_right
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
Jürgen Dippon
Pharmacogenomics, 2008
View PDFchevron_right
CYP2C19*2 and prognosis after an acute coronary syndrome: Insights from a Portuguese center
Gilberto Marques, Mario Freitas
Revista Portuguesa de Cardiologia (English Edition), 2012
View PDFchevron_right
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients
frédérick Allanic
Circulation: …, 2011
View PDFchevron_right
The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger
Frank Lichtenberg
NBER Chapters, 2018
View PDFchevron_right
Association between CYP2C19*2 variant and clinical outcome in Clopidogrel treated patients from Republic of Macedonia
Aleksandra Dimitrovska-Cvetkovska
View PDFchevron_right
Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients
Amein Al-Ali
International Journal of Cardiology, 2021
View PDFchevron_right
Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents
Asri Said
Pharmacogenomics, 2017
View PDFchevron_right
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
Klaus Tiroch
American Heart Journal, 2010
View PDFchevron_right